The principal objective of the annual PharmSource–Pharmaceutical Technology outsourcing survey is to gauge overall business trends in the contract manufacturing and research businesses. This year's edition documents an industry that is in good health but facing a new set of dynamics.
Examples of genuine strategic partnership agreements between end users and vendors are relatively rare in custom synthesis.
Quality must not only be part of the process, it must be a component from the start.
Risk assessment and management applies to technical matters as well as to interactions between organizations.
Industry must look at manufacturing as a competitive advantage, not just a way to get product out the door.
